Kevin B. Kim

21.3k total citations · 3 hit papers
116 papers, 8.2k citations indexed

About

Kevin B. Kim is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Kevin B. Kim has authored 116 papers receiving a total of 8.2k indexed citations (citations by other indexed papers that have themselves been cited), including 90 papers in Oncology, 75 papers in Molecular Biology and 20 papers in Immunology. Recurrent topics in Kevin B. Kim's work include Melanoma and MAPK Pathways (66 papers), Cutaneous Melanoma Detection and Management (50 papers) and CAR-T cell therapy research (26 papers). Kevin B. Kim is often cited by papers focused on Melanoma and MAPK Pathways (66 papers), Cutaneous Melanoma Detection and Management (50 papers) and CAR-T cell therapy research (26 papers). Kevin B. Kim collaborates with scholars based in United States, Australia and Switzerland. Kevin B. Kim's co-authors include Antoni Ribas, Jeffrey A. Sosman, Grant A. McArthur, K. B. Nolop, Richard J. Lee, Keith T. Flaherty, Igor Puzanov, Paul B. Chapman, Joseph F. Grippo and Peter J. O’Dwyer and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Kevin B. Kim

111 papers receiving 8.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

2010 2.6k citations Kevin B. Kim, Antoni Ribas et al. profile →
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial

2012 719 citations Gerald S. Falchook, Georgina V. Long et al. profile →
NRAS mutation status is an independent prognostic factor in metastatic melanoma

2011 528 citations Roland L. Bassett, Chaan S. Ng et al. Cancer profile →

Peers

Kevin B. Kim

ONCOL

PRM

IMMUN

Mathew J. Garnett United Kingdom

Ana Arance Spain

Gerald S. Falchook United States

Vanna Chiarion‐Sileni Italy

Alexander M. Menzies Australia

Wells A. Messersmith United States

Sarat Chandarlapaty United States

Lauren E. Haydu Australia

Suzanne F. Jones United States

Ryan B. Corcoran United States

Mathew J. Garnett United Kingdom

Kevin B. Kim

7.1k ×1.3

3.1k ×0.6

ONCOL

1.7k ×1.1

PRM

661 ×0.7

IMMUN

1.9k ×2.0

Citations per year, relative to Kevin B. Kim Kevin B. Kim (= 1×) peers Mathew J. Garnett

Countries citing papers authored by Kevin B. Kim

Since Specialization

Citations

This map shows the geographic impact of Kevin B. Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kevin B. Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kevin B. Kim more than expected).

Fields of papers citing papers by Kevin B. Kim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kevin B. Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kevin B. Kim. The network helps show where Kevin B. Kim may publish in the future.

Co-authorship network of co-authors of Kevin B. Kim

This figure shows the co-authorship network connecting the top 25 collaborators of Kevin B. Kim. A scholar is included among the top collaborators of Kevin B. Kim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kevin B. Kim. Kevin B. Kim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kim, Kevin B., Pierre‐Yves Desprez, David de Semir, et al.. (2025). Phase II Study of Niraparib in Patients With Advanced Melanoma With Homologous Recombination Pathway Gene Mutations. JCO Precision Oncology. 9(9). e2400658–e2400658. 1 indexed citations

Leong, Stanley P. L., et al.. (2024). Preoperative and Intraoperative Identification of Sentinel Lymph Nodes in Melanoma Surgery. Cancers. 16(15). 2767–2767. 2 indexed citations

Bezrookove, Vladimir, Sara Kianian, Robyn L. Jones, et al.. (2024). The Molecular Evolution of Melanoma Distant Metastases. Journal of Investigative Dermatology. 144(11). 2530–2540.e1. 5 indexed citations

Khattak, Adnan, Jeffrey S. Weber, Tarek Meniawy, et al.. (2023). Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial.. Journal of Clinical Oncology. 41(17_suppl). LBA9503–LBA9503. 50 indexed citations

Wang, Lin, et al.. (2023). Outcomes of patients with advanced NF1-mutant melanoma treated with MEK inhibitors.. Journal of Clinical Oncology. 41(16_suppl). e21513–e21513.

Minor, David R., Kevin B. Kim, Ricky T. Tong, et al.. (2022). A Pilot Study of Hepatic Irradiation with Yttrium-90 Microspheres Followed by Immunotherapy with Ipilimumab and Nivolumab for Metastatic Uveal Melanoma. Cancer Biotherapy and Radiopharmaceuticals. 37(1). 11–16. 10 indexed citations

Semir, David de, Vladimir Bezrookove, Mehdi Nosrati, et al.. (2021). Nuclear Receptor Coactivator NCOA3 Regulates UV Radiation–Induced DNA Damage and Melanoma Susceptibility. Cancer Research. 81(11). 2956–2969. 12 indexed citations

Han, Dale, Alexander C. J. van Akkooi, Richard J. Straker, et al.. (2021). Current management of melanoma patients with nodal metastases. Clinical & Experimental Metastasis. 39(1). 181–199. 8 indexed citations

Qin, Yong, Kathryn Bollin, Mariana Petaccia de Macêdo, et al.. (2020). Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy. Journal for ImmunoTherapy of Cancer. 8(2). e000960–e000960. 37 indexed citations

10.

Kashani–Sabet, Mohammed, James R. Miller, Serigne Lo, et al.. (2020). Reappraisal of the prognostic significance of mitotic rate supports its reincorporation into the melanoma staging system. Cancer. 126(21). 4717–4725. 14 indexed citations

11.

Kim, Kunhwa, Carol J. Etzel, Jinhyun Kim, et al.. (2018). Association between melanoma and renal-cell carcinoma for sequential diagnoses: A single-center retrospective study. Cancer Epidemiology. 57. 80–84. 6 indexed citations

12.

Kim, Dae Won, Lauren E. Haydu, Aron Y. Joon, et al.. (2016). Clinicopathological features and clinical outcomes associated with TP53 and BRAF^N^on‐^V⁶⁰⁰ mutations in cutaneous melanoma patients. Cancer. 123(8). 1372–1381. 34 indexed citations

13.

Hong, David S., Razelle Kurzrock, Jennifer J. Wheler, et al.. (2015). Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma. Clinical Cancer Research. 21(21). 4801–4810. 57 indexed citations

14.

Ascierto, Paolo A., David R. Minor, Antoni Ribas, et al.. (2013). Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma. Journal of Clinical Oncology. 31(26). 3205–3211. 338 indexed citations

15.

Davies, Michael A., Patricia S. Fox, Nicholas E. Papadopoulos, et al.. (2012). Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic Melanoma. Clinical Cancer Research. 18(4). 1120–1128. 39 indexed citations

16.

Kim, Kevin B., Richard Kefford, Anna C. Pavlick, et al.. (2012). Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF -Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor. Journal of Clinical Oncology. 31(4). 482–489. 356 indexed citations

17.

Kim, Kevin B., Jason Chesney, Douglas Robinson, et al.. (2011). Phase I/II and Pharmacodynamic Study of Dovitinib (TKI258), an Inhibitor of Fibroblast Growth Factor Receptors and VEGF Receptors, in Patients with Advanced Melanoma. Clinical Cancer Research. 17(23). 7451–7461. 100 indexed citations

18.

Kim, Kevin B., Jeffrey A. Sosman, John P. Fruehauf, et al.. (2011). BEAM: A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Melanoma. Journal of Clinical Oncology. 30(1). 34–41. 148 indexed citations

19.

Bedikian, Agop Y., Caimiao Wei, Michelle A. Detry, et al.. (2010). Predictive Factors for the Development of Brain Metastasis in Advanced Unresectable Metastatic Melanoma. American Journal of Clinical Oncology. 34(6). 603–610. 53 indexed citations

20.

Woodman, Scott E., Jonathan C. Trent, Katherine Stemke‐Hale, et al.. (2009). Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates. Molecular Cancer Therapeutics. 8(8). 2079–2085. 141 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact